抗糖尿病药物可以影响2型糖尿病患者的端粒长度吗? 一个小小的回顾
1Department of Endocrinology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.
Diabetes, metabolic syndrome and obesity : targets and therapy
|November 29, 2023
概括
某些抗糖尿病药物可能通过影响端粒长度来减缓2型糖尿病患者的衰老. 甲福明和西塔格利普丁显示出保护作用,而胰岛素可能会加速衰老.
科学领域:
- 内分泌学 在内分泌学.
- 老年学是一门学科.
- 分子生物学分子生物学
背景情况:
- 在2型糖尿病 (T2DM) 患者中,衰老加速.
- 端粒缩短是生物衰老的一个关键指标.
- 抗糖尿病药物正在研究它们的抗衰老特性.
研究的目的:
- 对T2DM患者的抗糖尿病药物和端粒长度 (TL) 之间的关联进行临床试验进行审查.
- 探索抗糖尿病药物如何通过端粒动态影响衰老.
主要方法:
- 临床试验的系统审查.
- 对对T2DM患者的端粒长度进行研究的研究分析,这些患者接受了各种抗糖尿病药物治疗.
主要成果:
- 在T2DM患者中,美特福明和西塔利普丁可能会保持端粒长度.
- 外源性胰岛素使用似乎与加速的端粒缩短有关.
- 由于纵向数据有限,关于阿卡尔和格莱布里德对T2DM中TL的影响的证据是不确定的.
结论:
- 抗糖尿病药物对T2DM中的端粒长度有不同的影响.
- 梅特福林和西塔格利普丁通过保护端粒,显示出潜在的抗衰老作用.
- 需要进一步的研究来澄清其他抗糖尿病药物在T2DM衰老中的作用.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones
209
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
209
Diabetes: Management and Pharmacotherapy
289
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
289
Carbohydrate Metabolism
11.2K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.2K
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Insulin: Dosing Regimen and Adverse Effects
181
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
181


